Generation Bio (GBIO) Competitors

$2.99
-0.27 (-8.28%)
(As of 05/10/2024 ET)

GBIO vs. ATOS, RIGL, ALIM, IXHL, OMER, LFCR, TELO, ELYM, GTHX, and VERU

Should you be buying Generation Bio stock or one of its competitors? The main competitors of Generation Bio include Atossa Therapeutics (ATOS), Rigel Pharmaceuticals (RIGL), Alimera Sciences (ALIM), Incannex Healthcare (IXHL), Omeros (OMER), Lifecore Biomedical (LFCR), Telomir Pharmaceuticals (TELO), Eliem Therapeutics (ELYM), G1 Therapeutics (GTHX), and Veru (VERU). These companies are all part of the "pharmaceutical preparations" industry.

Generation Bio vs.

Atossa Therapeutics (NASDAQ:ATOS) and Generation Bio (NASDAQ:GBIO) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, media sentiment, community ranking, risk, analyst recommendations, earnings and institutional ownership.

12.7% of Atossa Therapeutics shares are owned by institutional investors. Comparatively, 95.2% of Generation Bio shares are owned by institutional investors. 7.8% of Atossa Therapeutics shares are owned by insiders. Comparatively, 21.1% of Generation Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Atossa Therapeutics had 3 more articles in the media than Generation Bio. MarketBeat recorded 6 mentions for Atossa Therapeutics and 3 mentions for Generation Bio. Generation Bio's average media sentiment score of 0.97 beat Atossa Therapeutics' score of 0.00 indicating that Atossa Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Atossa Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Generation Bio
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Generation Bio's return on equity of -31.01% beat Atossa Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Atossa TherapeuticsN/A -31.01% -29.77%
Generation Bio N/A -52.29%-31.80%

Atossa Therapeutics currently has a consensus target price of $4.50, suggesting a potential upside of 202.01%. Generation Bio has a consensus target price of $8.00, suggesting a potential upside of 167.56%. Given Generation Bio's stronger consensus rating and higher probable upside, equities research analysts plainly believe Atossa Therapeutics is more favorable than Generation Bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Atossa Therapeutics
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Generation Bio
0 Sell rating(s)
4 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33

Atossa Therapeutics has a beta of 1.27, indicating that its stock price is 27% more volatile than the S&P 500. Comparatively, Generation Bio has a beta of 2.87, indicating that its stock price is 187% more volatile than the S&P 500.

Atossa Therapeutics received 192 more outperform votes than Generation Bio when rated by MarketBeat users. However, 66.67% of users gave Generation Bio an outperform vote while only 64.96% of users gave Atossa Therapeutics an outperform vote.

CompanyUnderperformOutperform
Atossa TherapeuticsOutperform Votes
228
64.96%
Underperform Votes
123
35.04%
Generation BioOutperform Votes
36
66.67%
Underperform Votes
18
33.33%

Atossa Therapeutics has higher earnings, but lower revenue than Generation Bio. Atossa Therapeutics is trading at a lower price-to-earnings ratio than Generation Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Atossa TherapeuticsN/AN/A-$30.09M-$0.24-6.21
Generation Bio$5.90M33.70-$126.61M-$1.96-1.53

Summary

Atossa Therapeutics beats Generation Bio on 9 of the 15 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GBIO vs. The Competition

MetricGeneration BioPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$222.74M$6.60B$5.02B$7.82B
Dividend YieldN/A2.74%37.56%3.95%
P/E Ratio-1.5311.46121.6614.35
Price / Sales33.70250.832,420.1574.95
Price / CashN/A32.5149.1236.49
Price / Book0.975.945.344.50
Net Income-$126.61M$139.96M$105.39M$217.43M
7 Day Performance-5.68%-2.00%-0.89%-0.15%
1 Month Performance-25.25%-5.63%-3.03%-1.64%
1 Year Performance-34.72%-1.98%4.21%8.89%

Generation Bio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ATOS
Atossa Therapeutics
2.1229 of 5 stars
$1.51
-1.3%
$4.50
+198.0%
+119.1%$189.20MN/A-6.2912Short Interest ↓
RIGL
Rigel Pharmaceuticals
1.8744 of 5 stars
$1.05
-1.9%
$5.81
+453.6%
-17.3%$184.17M$116.88M-7.00147Earnings Report
Analyst Forecast
Analyst Revision
News Coverage
ALIM
Alimera Sciences
2.6107 of 5 stars
$3.68
+0.3%
$7.50
+103.8%
+114.2%$192.65M$80.75M-1.70154Upcoming Earnings
Short Interest ↑
IXHL
Incannex Healthcare
0 of 5 stars
$2.89
+14.7%
N/A+31.6%$183.46M$930,000.000.003Short Interest ↑
OMER
Omeros
0.1729 of 5 stars
$3.15
+0.6%
N/A-42.1%$182.51MN/A-1.68196Upcoming Earnings
News Coverage
LFCR
Lifecore Biomedical
1.3973 of 5 stars
$6.42
-0.6%
$9.50
+48.0%
+39.2%$194.65M$103.27M-1.92459
TELO
Telomir Pharmaceuticals
0 of 5 stars
$6.62
-8.9%
N/AN/A$196.02MN/A0.001Gap Up
ELYM
Eliem Therapeutics
0 of 5 stars
$7.09
+41.2%
N/A+127.4%$196.54MN/A-4.829Short Interest ↓
Positive News
Gap Up
High Trading Volume
GTHX
G1 Therapeutics
3.7154 of 5 stars
$3.77
+1.3%
$9.33
+147.6%
+63.4%$197.21M$82.51M-3.97100Short Interest ↑
VERU
Veru
1.1575 of 5 stars
$1.35
+8.0%
$3.33
+146.9%
-10.7%$197.61M$16.30M-1.80189

Related Companies and Tools

This page (NASDAQ:GBIO) was last updated on 5/11/2024 by MarketBeat.com Staff

From Our Partners